This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Intra-Cellular (ITCI) Q1 Earnings Top, Caplyta Volume Rises
by Zacks Equity Research
Intra-Cellular (ITCI) first-quarter earnings and revenues beat estimates. The company reiterates its previously issued guidance for 2023.
Recent Price Trend in Ocuphire Pharma, Inc. (OCUP) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Ocuphire Pharma, Inc. (OCUP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Rise Y/Y
by Zacks Equity Research
Puma Biotechnology (PBYI) earnings and sales beat estimates in Q1. Stock rises in after-hours.
Ironwood (IRWD) Q1 Earnings Beat Estimates, Linzess Volume Up
by Zacks Equity Research
Ironwood (IRWD) reports better-than-expected results, wherein both earnings and revenues beat estimates. The strong momentum of Linzess continues with 10% growth in prescription demand.
Apellis (APLS) Q1 Earnings Miss, Empaveli & Syfovre Fuel Growth
by Zacks Equity Research
Apellis Pharmaceuticals' (APLS) loss in the first quarter is wider than estimates. Empaveli and Syfovre boost product revenues for the company.
Intellia (NTLA) Beats on Q1 Earnings, Gives Pipeline Update
by Zacks Equity Research
Intellia's (NTLA) first-quarter earnings beat estimates. The company provides updates on its gene-editing pipeline.
Ocuphire Pharma, Inc. (OCUP) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Ocuphire Pharma, Inc. (OCUP) closed at $5.86, marking a +0.86% move from the previous day.
Corcept (CORT) Misses on Q1 Earnings, Revises 2023 Sales Guidance
by Zacks Equity Research
Corcept (CORT) first-quarter earnings miss estimates, while revenues beat the same. The company gives updates on its pipelines and raises revenue guidance for 2023.
Zoetis (ZTS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Zoetis' (ZTS) first-quarter 2023 earnings beat estimates, while revenues miss the same. The company reiterates its financial guidance for 2023.
Amarin's (AMRN) Q1 Earnings Top, Vascepa Sales Fall
by Zacks Equity Research
Amarin's (AMRN) first-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.
Repligen (RGEN) Beats on Q1 Earnings, Lowers 2023 Guidance
by Zacks Equity Research
Repligen's (RGEN) first-quarter earnings and revenues beat estimates.
Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Intercept (ICPT) reports wider-than-expected loss in the first quarter of 2023. Revenues rise year over year.
BioMarin (BMRN) Q1 Earnings Top, Voxzogo Drives Sales
by Zacks Equity Research
BioMarin (BMRN) reports encouraging first-quarter results, wherein both earnings and sales beat estimates. The rapid uptake of Voxzogo boosts revenues.
Alkermes (ALKS) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) reports encouraging first-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.
Ocuphire (OCUP) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Occuphire (OCUP) is expected to provide updates on its proprietary ophthalmic platform for treating refractive and retinal eye disorders, on its first-quarter earnings call.
Wall Street Analysts Believe Ocuphire Pharma, Inc. (OCUP) Could Rally 257.14%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 257.1% upside potential for Ocuphire Pharma, Inc. (OCUP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Ocuphire Pharma, Inc. (OCUP) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Ocuphire Pharma, Inc. (OCUP) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Ocuphire Pharma, Inc. (OCUP) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Ocuphire Pharma, Inc. (OCUP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Masimo (MASI) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Masimo (MASI) and Ocuphire Pharma, Inc. (OCUP) have performed compared to their sector so far this year.
Ocuphire Pharma, Inc. (OCUP) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Ocuphire Pharma, Inc. (OCUP) closed at $5.36 in the latest trading session, marking a -0.56% move from the prior day.
Does Ocuphire Pharma, Inc. (OCUP) Have the Potential to Rally 323.89% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Ocuphire Pharma, Inc. (OCUP) points to a 323.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
4 Medical Stocks to Buy as Rate Hike Cycle Nears End
by Indrajit Bandyopadhyay
We have narrowed our search to four U.S.-based medical stocks with attractive valuations. These are HROW, LSTA, OCUP and PRE.
Here's Why Momentum in Ocuphire Pharma, Inc. (OCUP) Should Keep going
by Zacks Equity Research
Ocuphire Pharma, Inc. (OCUP) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
What Makes Ocuphire Pharma, Inc. (OCUP) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Ocuphire Pharma, Inc. (OCUP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Ocuphire Pharma, Inc. (OCUP) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?